Trouble logging in? Forgot password? We can help!
215-685-6784
215-238-6944
Fill out both forms, then either email or fax them to us at the contact above.
Provider? Stay in the know
Get the newest information from the Immunization Program right in your inbox!
Sign upNew Immigrant and Refugee Pediatric Vaccination This blog post was written alongside Dr. Mayssa Abuali, who has served the Philadelphia pediatric community for the past 10 years. At the first domestic health visit with new immigrant or refugee pediatric patients, clinicians should review all available vaccine records,...
New Meningococcal Vaccine for Pediatric Patients This blog post is part of a series highlighting essential changes in the 2024 ACIP immunization schedules. This series is written alongside Immunization Program Medical Specialist, Dr. Mayssa Abuali. Dr. Abuali is board-certified in general pediatrics, pediatric infectious diseases, and pediatric hospital...
Administration Errors: RSV for Infants On November 30, CDC alerted immunization programs that they have received reports of infants being mistakenly administered RSV vaccines intended for adults. Infants should only receive the RSV preventive antibody, nirsevimab (Beyfortus, Sanofi).RSV vaccines (Arexvy by GSK and Abrysvo by Pfizer) are...
Quality Improvement Opportunity for VFC Providers The Immunization Quality Improvement for Providers (IQIP) Program is a CDC initiative to help providers implement strategies that support their immunization activities. VFC-enrolled practices are chosen by the CDC for IQIP enrollment each year. However, starting this project year (July 1, 2023 to...
Vaccine Shipment Delays During the December Holiday Submit orders by Friday, December 8! During the holiday season – from mid-December to early January – the distribution center that ships vaccine provided through the Vaccines for Children (VFC), Vaccines for Adults at Risk (VFAAR), and Bridge Access programs...
Nirsevimab (Beyfortus) Updates Due to the unprecedented demand for nirsevimab, supply of this product is extremely limited through both the Vaccines for Children (VFC) program and the private market. Below is an update on available supply and tips on how to prioritize use of available doses....
Pneumococcal Vaccination for Asthmatic Pediatric Patients This blog post is part of a series highlighting important changes in the 2024 ACIP immunization schedules. This series is written alongside newly onboarded Immunization Program Medical Specialist, Dr. Mayssa Abuali. Dr. Abuali is board certified in general pediatrics, pediatric infectious...
Dosing of Moderna COVID-19 Vaccine (2023-2024 Formula) FDA released important information to ensure correct administration of the Moderna COVID-19 vaccine (2023-2024 formula) for individuals 6 months through 11 years. The announcement states that providers who administer Moderna COVID-19 vaccine (2023-2024 formula) to individuals ages 6 months through 11...
Supply Updates and Borrowing VFC Doses The nirsevimab supply shortage continues to evolve and is not expected to resolve soon. Review this CDC advisory with updates about nirsevimab supply and recommendations to prioritize the use of the limited supply of this product. With these limitations, the Immunization Program wants...
Nirsevimab (Beyfortus) and COVID-19 Updates Nirsevimab Due to high demand and limited supply cited by the CDC, nirsevimab (Beyfortus) ordering through VFC has been put on hold as of October 17, 2023. The CDC is working with Sanofi to secure a supply of this immunization within the...
2023-2024 Novavax Now Available to Order Novavax COVID-19 vaccine, adjuvanted (2023-2024 formula) is now available to order. 2023-2024Novavax is authorized for individuals 12 years and older. This product package contains two multi dose vials each containing five doses. The NDC for this product is NDC # 80631-0105-02. It can...
Beyfortus (nirsevimab) Now Available Through VFC On July 17, 2023, FDA licensed AstraZeneca and Sanofi’s Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD). On August 3, the ACIP voted unanimously to recommend nirsevimab for use in infants during the RSV...
Additional Vaccines Available for VFC Flumist and the Moderna 2023-24 COVID-19 vaccine for 6 mo – 11 yrs are now available to order for your VFC eligible patients through PhilaVax. FlumistEligibility: 2 - 18 yearsPackaging: 10 0.2 mL, intranasal sprayersCVX: 149CPT: 90672NDC: 66019-0310-10 View a step-by-step ordering guide. View more information...
VFC and VFAAR Shipping Delays Our vaccine distribution center is currently working through an unanticipated backlog of VFC and VFAAR orders as a result of having relocated. Due to this please be aware that there are likely to be delays with some vaccine shipments. For your September...
COVID-19 Vaccine Available to Order Through VFC and the Bridge Access Program On September 12, 2023, ACIP approved the use of updated COVID-19 vaccines. The new products are monovalent (single), Omicron variant XBB.1.5. Under the new recommendation, everyone over 6 months is eligible for an updated...
Pediatric Pneumococcal Vaccine Updates As a reminder, Prevnar 20 (PCV20, Pneumococcal 20-valent Conjugant Vaccine; NDC 00005-2000-10) is now available to order for your VFC eligible patients. Prevnar 13 (PCV13) is no longer available to order through the VFC program. Please read our previous advisory on these changes. To transition...
New Vaccine Product Available for VFC/VFAAR A one-vial presentation of Menveo (MenACYW-135) is now available through the Philadelphia VFC & VFAAR programs. This presentation does not require reconstitution. The Prescribing Information now describes both presentations of Menveo: the current two-vial presentation and a new one-vial presentation. One-vial Presentation (NEW) NDC: 58160-0827-30 For use in individuals 10 years through...
Private COVID-19 Vaccine Procurement Commercialization of COVID-19 vaccines is occurring next week. VFC Providers are required to match vaccines on the private side. We have created an FAQ to assist providers through this transition. Take these steps now to plan which COVID-19 vaccines you will purchase privately: Review the anticipated...
